Predictors of Loss to Follow-Up among HIV-Infected Adults after Initiation of the First-Line Antiretroviral Therapy at Arba Minch General Hospital, Southern Ethiopia: A 5-Year Retrospective Cohort Study
Table 2
Baseline clinical-, immunological-, and treatment-related characteristics of HIV-positive adults on ART in Arba Minch General Hospital, Southern Ethiopia, 2019 ().
Characteristics
Categories
Frequency ()
Percentage (%)
Initial regimen
498
98.0
3
0.6
4
0.8
3
0.6
ART pills per a day
One
491
96.7
Two
17
3.4
CPT at start of ART
Yes
284
55.9
No
224
44.1
Comedication other than CPT
Yes
111
21.9
No
397
78.2
TB at start
Yes
84
16.5
No
424
83.5
OIs other than TB at the start
Yes
85
16.7
No
423
83.3
Comorbidity other than OIs
Yes
11
2.2
No
497
97.8
Functional status
Working
395
77.8
Ambulatory and bedridden
113
22.2
WHO clinical stage
Stage I
271
53.4
Stage II
97
19.1
Stage III
124
24.4
Stage IV
16
3.2
Baseline weight (in kg)
≤60 kg
384
75.6
>60 kg
124
24.4
Baseline CD4 count (cells/mm3)
<100 cells/mm3
88
17.3
100–199 cells/mm3
89
17.5
200–349 cells/mm3
155
30.5
≥350 cells/mm3
176
34.7
Baseline HGB (g/dL)
<7 g/dL
10
2.4
7–9.9 g/dL
60
11.8
10–12.9 g/dL
306
60.2
≥13 g/dL
132
25.9
Baseline creatinine
0.00–0.59 mg/dL
93
18.3
0.6–1.2 mg/dL
379
74.6
>1.2 mg/dL
36
7.1
Baseline alanine transaminase (IU/L)
<7 IU/L
9
1.8
7–56 IU/L
472
92.9
>56 IU/L
27
5.31
Drug side effect
Yes
157
30.9
No
351
69.1
Treatment duration
<1 year
198
38.9
1–2 years
109
21.5
>2 years
201
39.6
ART: antiretroviral therapy; AZT: zidovudine; CD4: clusters of differentiation; CPT: cotrimoxazole prophylaxis therapy; EFV: efavirenz; HGB: hemoglobin; IU/L: international unit per liters; kg: kilogram; TDF: tenofovir; +3TC: lamivudine; NVP: nevirapine; TB: tuberculosis; OIs: opportunistic infections; WHO: World Health Organization.